Filing Overview
Company: Pliant Therapeutics, Inc. (Nasdaq: PLRX)
Filing: Form 8-K filed March 8, 2023, reporting events effective March 6, 2023. The filing concerns board appointments and compensatory arrangements, not quarterly or annual financial results.
Business Context and Reporting Period
The Board increased its authorized size from eight to ten members, creating one Class I vacancy, with a term expiring at the 2024 annual meeting, and one Class II vacancy, with a term expiring at the 2025 annual meeting.
Key Financial and Operating Metrics
- The filing does not provide revenue, profit or loss, cash flow, margin, debt, liquidity, guidance, or other operating performance metrics.
- No clear financial statement information or comparable-period data is included.
Material Changes
- Thomas McCourt was appointed to the Board as a Class II director and appointed to the Compensation Committee.
- Darren Cline was appointed to the Board as a Class I director and appointed to the Audit Committee.
- The Board determined that both directors are independent and qualified under applicable SEC and Nasdaq requirements.
- The filing states that there are no arrangements or understandings supporting either appointment and no related-party transaction requiring disclosure under Item 404(a) of Regulation S-K.
Compensation, Outlook, and Risks
- Each director will receive a prorated annual board retainer of $40,000.
- Mr. McCourt will receive a prorated annual Compensation Committee retainer of $5,000.
- Mr. Cline will receive a prorated annual Audit Committee retainer of $7,500.
- Each director received an option to purchase 22,000 shares of common stock, vesting in substantially equal monthly installments over three years, subject to continued Board service.
- The Company will enter into its standard indemnification agreement with each director.
- The filing does not provide management guidance, clinical or commercial outlook, contingencies, or unusual financial items.
Investor Verification Points
- Confirm the directors’ backgrounds, independence determinations, and committee assignments in subsequent proxy materials.
- Review the applicable non-employee director compensation plan and option terms for complete vesting, exercise, and expiration provisions.
- Assess the potential dilution from the two 22,000-share option grants.
- Use the Company’s periodic reports, rather than this 8-K, to verify financial performance, cash runway, liquidity, debt, and operating outlook.